PHARMA - Relationships

Relationships Table

Entities - Color - Target Drug Disease Lo Med Hi
Aurora B kinase 415 Target Target Aurora A kinase 318 14 0.04 -0.96 0.04 0.79
CD1A 2,739 Target Target CD34 24,598 317 0.04 -0.93 0.12 0.71
ERK1 18,374 Target Target EGF 27,487 878 0.04 -0.96 0.05 0.71
Analgesia 44,857 Disease Target Mu Opioid Receptor 4,576 567 0.04 -0.93 0.12 0.70
BMP-2B 18 Target Target BMP-4 1,255 6 0.04 -0.81 0.33 0.74
CXCL10 2,386 Target Target CCL1 220 29 0.04 -0.93 0.13 0.75
ERBB4 994 Target Target EGF 27,487 210 0.04 -0.88 0.21 0.70
C5a 4,164 Target Target Platelet Activating Factor 9,915 259 0.04 -0.96 0.06 0.73
Kappa-Type Opioid Receptor 4 Target Target Sphingosine 1-Phosphate Receptor 1 150 1 0.04 -0.86 0.25 0.77
CCL5 2,002 Target Target CXCL3 145 22 0.04 -0.92 0.15 0.75
Diabetic Nephropathy 12,496 Disease Target Renin 43,456 953 0.04 -0.95 0.08 0.70
Cancer 1,053,491 Disease Target Erbb2 4,536 2,833 0.04 -0.61 0.62 0.63
4-1BB Receptor 20 Target Target CD137 474 4 0.04 -0.89 0.20 0.76
Alpha-Glucosidase 4,319 Target Target Pancreatic Alpha-Amylase 423 56 0.04 -0.93 0.13 0.74
CCL19 658 Target Target CXCL9 1,016 34 0.04 -0.96 0.05 0.78
CD4 112,219 Target Target CD14 9,941 1,398 0.04 -0.92 0.14 0.68
Arixtra (Fondaparinux Sodium)- FDA 16 Drug Target Bivalirudin 891 5 0.04 -0.83 0.31 0.75
Tissue-Type Plasminogen Activator 5,020 Target Target D-Dimer 6,185 235 0.04 -0.96 0.05 0.75
BAFFR 44 Target Target BLyS 457 6 0.04 -0.92 0.14 0.77
CXCL9 1,016 Target Target CXCL2 750 37 0.04 -0.96 0.05 0.78
Arthritis 128,324 Disease Target Collagen 138,882 5,668 0.04 -0.96 0.04 0.68
Bivalirudin 891 Target Target Eptifibatide 772 36 0.04 -0.96 0.05 0.79
CD68 6,424 Target Target CD34 24,598 546 0.04 -0.95 0.08 0.72
CXCL11 526 Target Target CXCL3 145 12 0.04 -0.95 0.08 0.78
CXCL11 526 Target Target CXCL4/PF4 9 3 0.04 -0.81 0.33 0.76
Platelet Aggregation 25,460 Disease Target Eptifibatide 772 194 0.04 -0.86 0.25 0.71
CD14 9,941 Target Target Toll-Like Receptor 2 2,174 204 0.04 -0.94 0.09 0.73
CXCL16 341 Target Target CXCL9 1,016 26 0.04 -0.95 0.08 0.77
EPHA2 532 Target Target EPHB1 137 12 0.04 -0.94 0.09 0.78
EGF 27,487 Target Target ERBB3 1,154 251 0.04 -0.88 0.22 0.71
CCL18 256 Target Target CCL3 1,427 27 0.04 -0.94 0.11 0.76
Myeloperoxidase 16,181 Target Target Elastase 13,875 671 0.04 -0.96 0.05 0.74
CD146 729 Target Target CD34 24,598 190 0.04 -0.86 0.26 0.71
CCL4 5,638 Target Target CXCL10 2,386 165 0.04 -0.95 0.07 0.75
A1M 59 Target Target B2M 677 9 0.05 -0.91 0.15 0.77
ELC 355 Target Target DC-CK1 22 4 0.05 -0.90 0.18 0.77
CCL19 658 Target Target CCL5 2,002 52 0.05 -0.95 0.08 0.77
CCL7 274 Target Target CXCL9 1,016 24 0.05 -0.94 0.09 0.77
Erbb2 4,536 Target Target EGF 27,487 513 0.05 -0.93 0.11 0.72
CCL3 1,427 Target Target CXCL3 145 21 0.05 -0.92 0.14 0.76
Epigen 27 Target Target beta-Cellulin 17 1 0.05 -0.95 0.06 0.83
Carcinoma 433,099 Disease Target CEA 17,022 4,013 0.05 -0.87 0.24 0.65
CXCL9 1,016 Target Target CCL8 197 21 0.05 -0.94 0.11 0.77
EPHA3 140 Target Target EPHB2 385 11 0.05 -0.95 0.08 0.79
Exodus-2 27 Target Target CCL21 808 7 0.05 -0.86 0.26 0.76
Adenosine A3 Receptor 164 Target Target Adenosine A1 Receptor 1,432 23 0.05 -0.92 0.14 0.76
EPHA2 532 Target Target EPHA3 140 13 0.05 -0.94 0.09 0.78
CXCL16 341 Target Target CXCL10 2,386 43 0.05 -0.93 0.13 0.76
Draflazine 33 Drug Target Equilibrative Nucleoside Transporter 1 211 4 0.05 -0.93 0.12 0.79
EPHA4 357 Target Target EPHB3 118 10 0.05 -0.94 0.08 0.79